South Centre Submission to USITC, 17 March 2023
Submission by the South Centre to the USITC hearing on Covid-19 diagnostics and therapeutics
India, South Africa and co-sponsors made a proposal for a waiver to certain provisions of the provisions of the WTO Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) in March 2020. In June 2022, the WTO Ministerial Decision on the TRIPS Agreement provided a partial waiver to obligations in Article 31, namely an exception to the 31.f export restrictions, in relation to patents for Covid-19 vaccines. No decision has yet been made with respect to diagnostics and therapeutics for Covid-19.
In this context, the U.S. Trade Representative (USTR) requested the U.S. International Trade Commission (USITC) to prepare a report on Covid-19 diagnostics and therapeutics.
Read below the submission by the South Centre to the USITC investigation: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities (Inv. No. 332-596).
This article was tagged: Access to Medicines, COVID-19, Diagnostics, Doha Declaration on the TRIPS Agreement and Public Health, Flexibilities, Intellectual Property, Intellectual Property Rights (IPRs), Pandemic, Pandemic Preparedness and Response, Patent, Public Health, Technology Transfer, Therapeutics, TRIPS, TRIPS Agreement, TRIPS Flexibilities, TRIPS Waiver, U.S. International Trade Commission (USITC), Vaccines, WTO Ministerial Decision on the TRIPS Agreement, WTO TRIPS Decision on COVID-19 Vaccines